Recent Dealtalk Insights
Best partnering practices – just common sense, part 1
February 9, 2010 : best practice
In Volume 5 No. 11/12 of the euroPLX Business Developer (download from www.europlx.com if you haven’t seen it), there was an interesting article about views of best partnering practices. more »
Medtech companies bank on EuroMedtech for financing and partnerships
January 25, 2010 :
In only its second year, EBD Group’s partnering event for the medical technology industry, EuroMedtech™, has become the premier destination for emerging innovator companies and start-ups to seek out and secure funding. more »
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
November 17, 2009 : Abbott, AstraZeneca, Bayer, big pharma, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, J&J, Merck, Novartis, patents, Pfizer, Roche, Sanofi
As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma* is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines. more »
Key terms for robust licensing
October 8, 2009 : best practice, licensing, partnering terms
By Susie Slaughter, Slaughter and May
Whatever the economic climate, licences warrant careful drafting since they are generally long-lasting agreements. In the biotechnology arena they also have an important role for both licensors and licensees in demonstrating commercial progress. more »
Business speed dating at BIOTECHNICA 2009
August 4, 2009 : partnering
Developing new business contacts is often time-consuming and costly. For this reason BIOTECHNICA now offers an affordable and speedy way for individuals and companies to link up with potential customers, suppliers and business partners more »
Biosimilars in the EU: delivering the goods?
March 5, 2009 : biosimilars
In January 2009, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama’s handling of the generic biotech issue, will be the defining issue of 2009 and beyond. more »
Strategic tips for adding value to licensing transactions
November 27, 2008 :
by Simon Rowell, James & Wells Intellectual Property
Website: James & Wells Intellectual Property
Introduction
A licence is permission to do something that would, in the absence of permission, infringe intellectual property rights. It is different to an assignment, which is a transfer of ownership of the intellectual property more »
Opportunity knocks for big pharmaceutical companies in the credit crunch
October 16, 2008 : big pharma, innovation, patents, Pfizer
Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich. As a result, pharmaceutical companies should weather the financial storm and be able to make significant acquisitions, unlike their biotechnology counterparts. more »
IP Financing: the Ten Commandments
October 6, 2008 : best practice, IP
By Jeremy Philips more »
The Challenge of IP Financing
October 2, 2008 : financings, IP
by Lorin Brennan
A growing share of commerce in today’s global information economy revolves around IP assets rather than the physical commodities that dominated the industrial age. more »
Recent company insights
Blog in Blog: There are no posts that match the selection criteria. View more company insights
Recent therapy insights
Blog in Blog: There are no posts that match the selection criteria. View more therapy insights
Recent technology insights
Blog in Blog: There are no posts that match the selection criteria. View more technology insights